Mergers & Acquisitions ·
Sells SYN-004 antibiotic portfolio to Biossil for $350K upfront plus up to $91M in milestones
TOVXTheriva Biologics, Inc.
Theriva Biologics sold its SYN-004 (ribaxamase) and related antibiotic-degrading enzyme assets, including SYN-006, to Biossil Labs Inc. for a non-refundable $350,000 upfront payment received at closing on October 30, 2026. Theriva retains rights to receive up to $3 million in regulatory milestones and up to $88 million in sales milestones based on cumulative worldwide net sales thresholds, along with low-single-digit royalties capped at $250 million. Biossil assumes full responsibility for future development and commercialization of the portfolio. The company is a diversified clinical-stage biopharmaceutical firm developing therapeutics for cancer and related diseases.